Calmark is already developing a point-of-care diagnostic instrument (POC) for newborns, where LDH is one of the tested biomarkers. During childbirth, newborns can suffer from lack of oxygen (asphyxia), which leads to an increase of LDH in the blood.
By adapting the measuring range to adult patients, an LDH test for assessment of severity in COVID-19 could be developed quickly. The test is based on the same test cassette and instrument as the Neo products.
The measuring instrument can be used close to the patient, for example in an emergency room. The platform consists of a portable instrument and a single-use test cassette for LDH.
Calmark POC-Analyzer is a portable, battery-powered and self-instructional instrument that will work with Calmark's POC test cassette. Each test contains the information required for automatic calibration of the results. When closing the lid of the instrument, the test is activated and a numeric value is displayed on the screen.
Blood samples may be analyzed wherever the patient is located, for example in an emergency room. The platform is adapted for hospital environment and is intended for in vitro diagnostics.
The Calmark COVID19-LDH test measures the concentration of LDH in whole blood in patients diagnosed with the SARS-CoV-2 virus. The test is used to assess the degree of disease in COVID-19.